Alaunos Therapeutics/ US98973P3091 /
2024-09-20 8:40:43 PM | Chg. -0.07 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
2.77USD | -2.47% | 1,097 Turnover: 3,044.20 |
-Bid Size: - | -Ask Size: - | 2.78 | 2.77 |
GlobeNewswire
06-10
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer...
GlobeNewswire
01-29
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
GlobeNewswire
2023-11-14
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Conti...
GlobeNewswire
2022-03-16
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
GlobeNewswire
2022-03-08
Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
GlobeNewswire
2022-01-26
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics